Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates

Core Insights - Thermo Fisher Scientific (TMO) reported quarterly earnings of $5.79 per share, exceeding the Zacks Consensus Estimate of $5.5 per share and up from $5.28 per share a year ago [1] - The company achieved revenues of $11.12 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.99% and increasing from $10.6 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +5.27%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - The previous quarter's earnings were also above expectations, with actual earnings of $5.36 compared to an expected $5.22, resulting in a surprise of +2.68% [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $6.48, with expected revenues of $11.78 billion, and for the current fiscal year, the estimate is $22.50 on revenues of $43.92 billion [8] - The estimate revisions trend for Thermo Fisher was unfavorable prior to the earnings release, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [7] Industry Context - Thermo Fisher operates within the Zacks Medical - Instruments industry, which is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry backdrop [9] - The performance of Thermo Fisher's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]